Document Detail


Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy.
MedLine Citation:
PMID:  8914031     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Treatment of hypertension with ACE inhibitors in diabetic patients reduces proteinuria and slows progression of nephropathy compared with agents that do not maintain declines in proteinuria. Calcium channel blockers (CCBs) have variable effects on proteinuria; their long-term effects on progression of diabetic nephropathy are not known. The current study examines the hypothesis that CCBs that maintain reductions in proteinuria slow progression of nephropathy associated with non-insulin dependent diabetes mellitus (NIDDM) by a degree comparable to ACE inhibitors, given similar levels of blood pressure control. To test this hypothesis we randomized 52 patients with NIDDM associated nephropathy and hypertension, mean age of 63 +/- 8 years, to either the ACE inhibitor, lisinopril (N = 18), nondihydropyridine CCBs (NDCCBs), verapamil SR (N = 8) or diltiazem SR (N = 10), or the beta blocker, atenolol (N = 16). Goal blood pressure was < or = 140/90 mm Hg. Patients were followed for a mean period of 63 +/- 7 months. The primary end point was change in creatinine clearance (CCr) slope in each group. There was no significant difference in mean arterial pressure reduction among the groups over the study period (P = 0.14). The mean rate of decline in CCr was greatest in the atenolol group (-3.48 ml/min/year/1.73 m2; P < 0.0001). There was no difference in the CCr slopes between lisinopril and NDCCBs groups (P = 0.36). Proteinuria was reduced to a similar extent in the lisinopril and NDCCBs groups (P > 0.99). Therefore, in persons with renal insufficiency secondary to NIDDM, similar levels of blood pressure control with either lisinopril or NDCCBs slowed progression of renal disease to a greater extent than atenolol. Moreover, this enhanced slowing of renal disease progression correlated with sustained and significant reductions in proteinuria, findings not observed in the atenolol group.
Authors:
G L Bakris; J B Copley; N Vicknair; R Sadler; S Leurgans
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Kidney international     Volume:  50     ISSN:  0085-2538     ISO Abbreviation:  Kidney Int.     Publication Date:  1996 Nov 
Date Detail:
Created Date:  1997-03-04     Completed Date:  1997-03-04     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0323470     Medline TA:  Kidney Int     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1641-50     Citation Subset:  IM    
Affiliation:
Department of Medicine, Ochsner Clinic, New Orleans, Louisiana, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Antihypertensive Agents / adverse effects,  therapeutic use*
Blood Glucose / metabolism
Blood Pressure / drug effects
Calcium Channel Blockers / adverse effects,  therapeutic use*
Creatinine / blood,  metabolism
Diabetes Mellitus, Type 2 / blood,  complications*
Diabetic Nephropathies / blood,  physiopathology,  prevention & control*
Disease Progression
Double-Blind Method
Female
Follow-Up Studies
Humans
Male
Middle Aged
Prospective Studies
Proteinuria / etiology
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Blood Glucose; 0/Calcium Channel Blockers; 60-27-5/Creatinine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Increased renal tubular expression of transforming growth factor beta in human allografts correlates...
Next Document:  Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and...